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TH17 cells are recognized as a unique subset of T helper cells that have critical roles in the 
pathogenesis of autoimmunity and tissue inflammation. Although RoRγt is necessary for the 
generation of TH17 cells, the molecular mechanisms underlying the functional diversity of TH17 
cells are not fully understood. Here we show that a member of interferon regulatory factor (IRF) 
family of transcription factors, IRF8, has a critical role in silencing TH17-cell differentiation. mice 
with a conventional knockout, as well as a T cell-specific deletion, of the Irf8 gene exhibited 
more efficient TH17 cells. Indeed, studies of an experimental model of colitis showed that IRF8 
deficiency resulted in more severe inflammation with an enhanced TH17 phenotype. IRF8 was 
induced steadily and inhibited TH17-cell differentiation during TH17 lineage commitment at 
least in part through its physical interaction with RoRγt. These findings define IRF8 as a novel 
intrinsic transcriptional inhibitor of TH17-cell differentiation. 
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C
D4 +  T helper (TH) T cell subsets are characterized by the 
secretion of unique cytokine profiles and have critical roles 
in orchestrating adaptive immune responses. In addition to 
TH1 and TH2 cells, TH17 cells have been identified more recently 
as  a  third  TH  subset  mediating  inflammatory  and  autoimmune 
responses through the production of interleukin (IL)-17A, IL-17F 
and IL-22 (refs 1–4). TH17 lineage commitment is initially driven 
by transforming growth factor (TGF)-β in the presence of IL-6 or 
IL-21 (refs 5–8), whereas IL-23 serves to expand or maintain TH17 
populations2,5,9,10. The orphan nuclear receptor, RORC, also known 
as RORγt, has been identified as the master transcription factor   
for TH17 development11. The differentiation of TH17 cells is also regu-
lated by several recently described positive and negative feedback 
loops involving IL-21, IL-23R, IL-10 and IL-27 (refs 6, 7, 12–15), 
indicating  that  intrinsic  genetic  programmes  may  contribute  to   
the  silencing  of  TH17  lineage  commitment.  There  is  increasing   
evidence that TH17 cells are involved in the pathogenesis of various 
autoimmune/inflammatory  diseases, including  multiple  sclerosis, 
rheumatoid arthritis, inflammatory bowel diseases and asthma16. 
Thus, a more complete understating of the molecular mechanisms 
involved  in  the  regulation  of  TH17  immune  responses  should   
provide  insights  into  the  pathogenesis  and  treatment  of  these   
and  possibly  other  inflammatory  diseases.  Several  transcription 
factors, including RORγt, RORα, STAT3 and interferon regulatory 
factor (IRF)4, have been reported to be important for TH17-cell   
differentiation.  However,  the  silencing  programme  for  TH17-cell 
differentiation has not been fully examined.
IRF8,  a  member  of  the  IRF  family,  is  expressed  by  B  cells,   
dendritic  cells  (DCs),  macrophages17–19  and  activated  T  cells20,21, 
and has been shown to have a diverse roles in the regulation of 
innate and adaptive immune responses. IRF8 has a DNA-binding 
domain in the amino (N)-terminal half of the protein and an IRF 
association domain in the carboxy (C) terminus that is responsi-
ble for heterodimerization with other transcription factors22. IRF8 
functions as a transcriptional repressor or activator depending on 
the formation of different heterodimeric DNA-binding complexes   
with partners that include members of the ETS family and the IRF 
family22. It is known that IRF8 has critical roles in the differentiation 
of myeloid cells, promoting monocyte over granulocyte differentia-
tion23. It is also a crucial regulator of many aspects of DC develop-
ment,  differentiation  and  function24,  thereby  having  an  essential   
role in the establishment of innate immune responses. Although 
IRF8 is critical for the regulation of immune cell growth, differen-
tiation and survival25, the direct effects of IRF8 on T-cell activation 
and differentiation are incompletely understood.
In the present study, we show that mice deficient in IRF8 because 
of a conventional knockout (KO) or with a T cell-specific conditional 
deletion exhibited enhanced TH17-cell differentiation while exhibi-
ting no significant effects on TH1 or TH2 cells. In addition, trans-
fer of naive T cells from IRF8-deficient mice induced more severe 
colitis in Rag–/– mice than T cell from normal controls. Furthermore,   
we report that IRF8 physically interacts with RORγt, resulting in 
inhibition of IL-17 transcription. These findings suggest that IRF8 
has a suppressive role in the control of TH17 differentiation and 
highlight the importance of intrinsic genetic programmes for the 
silencing of TH17-dependent immune responses.
Results
IRF8 deficiency enhances TH17-cell differentiation. To investigate 
the function of IRF8 in T cells, we first examined the expression 
of IRF8 in CD4 +  T cells from normal or OT-II transgenic mice 
activated by different stimuli. We found that T-cell antigen receptor 
(TCR)  engagement  with  anti-CD3  and  anti-CD28  antibodies  as 
well as stimulation of OT-II cells resulted in significant induction 
of  IRF8  protein  expression,  as  determined  by  western  blotting 
(Supplementary Fig. S1a,b). Interestingly, IRF8 protein was more 
stably expressed in naive CD4 +  T cells polarized for 12 to 72 h 
under  TH17-inducing  conditions  compared  with  TH1-  or  TH2-
inducing  conditions  (Supplementary  Fig.  S1a).  To  clarify  how 
TH17-polarizing conditions induce stable IRF8 expression, CD4 +  
cells were stimulated with TGF-β in the absence of TCR activation 
and the results showed that TGF-β clearly induced IRF8 expression 
at both 48 and 72 h (Supplementary Fig. S1c). In addition, mitogen-
activated  protein  kinase  inhibitors  significantly  blocked  IRF8 
protein  expression  induced  by  TCR  activation  (Supplementary 
Fig. S1d) and STAT3 mutant mice showed impaired IRF8 mRNA 
expression (Supplementary Fig. S1e). These data indicate that IRF8 
is consistently elevated in activated CD4 +  T cells and TCR signalling 
cascade is involved in induction of IRF8 expression.
We then assessed the contributions of IRF8 to TH17 differentia-
tion by studying CD4 +  T cells from mice deficient in IRF8 due to a 
conventional KO of the gene (Irf8–/– mice). Naive CD4 +  T cells from 
Irf8–/– or wild-type (WT) littermate mice were primed in vitro for   
4 days under TH0 or TH17 polarizing conditions. The cells were then 
re-stimulated  with  phorbol  myristate  acetate  (PMA)/ionomycin 
and examined for the percentages of IL-17-producing cells by intra-
cellular  staining  using  flow  cytometry.  Notably,  the  frequency  of 
IL-17-producing  cells  generated  from  Irf8–/–  T-cell  cultures  was 
about threefold greater than cells from WT cultures (Fig. 1a). These 
observations correlated with enhanced IL-17 secretion by Irf8–/– TH 
cells generated under TH17 polarizing conditions as determined by 
enzyme-linked immunosorbent assay (ELISA; Fig. 1b). In addition, 
IL-17-producing CD4 +  T cells were significantly increased among 
lamina propria lymphocytes isolated from Irf8–/– mice as compared 
with WT littermate controls following in vitro activation under TH17 
conditions or at the basal levels (Fig. 1c and Supplementary Fig. S2).
To determine whether the effects of IRF8 deficiency on TH17 
potential were cell type-specific, we next compared CD4 +  T cells   
from mice expressing Lck-Cre that were WT (wt/wt) or homozygous 
(fl/fl) for a conditional allele of Irf8 gene resulting in selective deple-
tion  of  IRF8  in  the  T-cell  compartment.  Quantitative  real-time 
reverse  transcrption(RT)–PCR  (qPCR)  analyses  revealed  dra-
matically lower levels of Irf8 transcripts in sorted thymocyte sub- 
populations  (DP,  CD4SP,  CD8SP)  and  splenic  CD3 + CD4 +   cells 
from  Lck-Cre + Irf8fl/fl  compared  with  cells  from  Lck-Cre + Irf8wt/wt  
littermate control mice (Supplementary Fig. S3), confirming that 
the Irf8 gene was efficiently deleted from Lck-Cre + Irf8fl/fl T cells. 
Splenic and lymph node CD4 +  T-cell subsets from mice with IRF8-
deficient T cells as well as from mice homozygous for a conventional 
Irf8 null allele were normal in number as well as in expression of the 
T-cell activation markers CD62L, CD44, CD25 and CD69. Expres-
sion of FOXP3 in thymic and peripheral lymph node T cells from 
mice of both genotypes was also similar (Supplementary Fig. S4), 
indicating that CD4 +  T cells develop normally in the absence of 
IRF8. Naive CD4 +  T cells from Lck-Cre + Irf8fl/fl and Lck-Cre + Irf8wt/wt  
littermate controls were subjected to TH17 polarization. As expected, 
TH cells from mice with a T cell-specific deficiency in IRF8 showed 
a remarkable increase in the generation of IL-17-producing cells   
(Fig. 1d) in association with significantly elevated levels of IL-17 secre-
tion (Fig. 1e). These results excluded the possibility that the effects 
of IRF8 deficiency on T cells from mice with a conventional KO of 
the gene could be attributed to the altered activities of other subsets 
of IRF8-deficient cells, such as B cells, DC or macrophages. TH17 
cells generated from splenic T cells of Irf8–/– mice comprised a major 
portion of the β-TCR +  CD4 +  lymphocyte subset (Supplementary 
Fig. S5). Indeed, high levels of IRF8 protein expression were detected 
in CD4 +  T cells polarized under TH17 conditions as determined by 
immunoblot analyses (Fig. 1f). Accordingly, transcript levels of the 
iconic TH17 cytokines IL-17A, IL-17F and IL-22 were enhanced in   
Irf8–/– TH17 cells (Fig. 1g). In contrast, TH1 or TH2 differentiation   
was  not  noticeably  affected  in  Irf8–/–  T-cell  cultures  (Fig.  2a–c).   
In addition, [3H]-Thymidine incorporation assay showed that the   ARTICLE     
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proliferation of CD4 +  T cells from Lck-Cre + Irf8fl/fl and Lck-Cre + -
Irf8wt/wt  mice  cultured  under  TH17  conditions  was  comparable   
(Fig. 2d). Taken together, these results indicate that IRF8 is induced 
during  T-cell  activation,  and  that  TH17-cell  differentiation  is 
enhanced in cells deficient in IRF8.
Treg cells and autocrine cytokines are not altered in Irf8–/– mice. 
To understand whether alterations in Treg cells might contribute 
to enhanced TH17 differentiation in IRF8-deficient mice, we ana-
lysed FOXP3 +  CD4 +  T cells in these mice. There were no significant   
differences between the FOXP3 +  CD4 +  T-cell populations of WT 
and Irf8–/– mice under TH17- or Treg-inducing conditions (Fig. 3a,b). 
Thus, the more efficient generation of Irf8–/– TH17 cells in response 
to the combined effects of TGF-β plus IL-6 was not because of   
alterations in TGF-β-derived Treg suppression. IL-17-producing cells 
generated from Irf8–/– T-cell cultures were greatly increased follow-
ing stimulation with IL-6 plus TGF-β (Fig. 3c).
To  further  investigate  how  IRF8  affects  TH17  differentiation, 
naive WT and Irf8–/– CD4 +  T cells were subjected to TH17 differ-
entiation in the presence of IL-6, IL-23 and TGF-β, either alone or 
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Figure 1 | Increased IL-17 production in IRF8 deficient T helper cells. (a) naive CD4 +  T cells from wild-type (WT) or Irf8–/– mice were differentiated 
under TH0 and TH17 polarizing conditions for 4 days. Cells were then re-stimulated with PmA/ionomycin for 5 h, stained for intracellular IL-17 and IFn-γ, 
and analysed by flow cytometry. Representative fluorescence-activated cell sorting (FACs) dot plots gated on CD4 +  cells and the percentages of IL-17-
producing CD4 +  cells are shown. Data are from one experiment representative of three independent experiments. Error bars, s.d. (b) The cells prepared 
in a, TH1 and TH2 polarizing conditions were re-stimulated with PmA/ionomycin for 24 h and the supernatants were analysed for IL-17 by ELIsA. Data are 
from one experiment representative of three independent experiments. Error bars, s.d. (c) Wild-type or Irf8–/– lamina propria lymphocytes (LPL) were 
differentiated under TH17 conditions for 4 days. Cells were then re-stimulated with PmA/ionomycin for 5 h, stained for intracellular IL-17 and analysed by 
flow cytometry. (d) naive CD4 +  T cells from Lck-Cre + Irf8wt/wt and Lck-Cre + Irf8fl/fl mice were differentiated under TH0 and TH17 polarizing conditions for 4 
days and the cells were re-stimulated with PmA/ionomycin for 5 h for staining of IL-17, IFn-γ and FoXP3. Representative FACs dot plots gated on CD4 +  
cells are shown. (e) The cells prepared in d were re-stimulated with PmA/ionomycin for 24 h and the supernatants were analysed for IL-17 by ELIsA.  
Data are from one experiment representative of two independent experiments. Error bars, s.d. (f) naive CD4 +  T cells from C57BL/6 mice were 
differentiated under TH0 and TH17 conditions for 4 days. The cells were re-stimulated with PmA/ionomycin for 12 h and IRF8 expression was analysed 
by western blot. (g) The cells prepared in a were re-stimulated with PmA/ionomycin for 5 h and mRnA expression of indicated genes was determined 
by qPCR. The data shown were normalized to levels of ubiquitin expression as analysed by qPCR. The results are representative of three independent 
experiments. Error bars, s.d.ARTICLE
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in various combinations, and then examined for the expression of   
lineage-specific  genes  by  qPCR.  Neither  IL-6  nor  TGF-β  alone 
induced significant levels of IL-17 or IL-17F transcripts (Fig. 3d). 
In contrast, dramatic increases in IL-17 and IL-17F transcripts were 
induced at multiple time points by the combination of IL-23, IL-6 and 
TGF-β in cultures of both Irf8–/– and WT T cells (Fig. 3d). Increased 
expression of IL-17 was confirmed at the protein level by ELISA   
(Fig. 3e–g). IL-23 induced low levels of IL-17 and IL-17F transcripts 
with no significant differences being seen between CD4 +  T cells of 
WT and Irf8–/– mice (Fig. 3d). This suggests that IRF8 may not target   
the IL-23 signalling cascade, but may exert a major influence on TH17 
differentiation instead of TH17 expansion and maintenance.
IL-21,  an  autocrine  cytokine  produced  by  CD4 +   T  follicular 
helper cells and TH17 cells6,7, induces TH17 differentiation in the 
presence  of  TGF-β.  IRF8-deficient  T  cells  displayed  enhanced 
induction of TH17-associated molecules following stimulation by 
TGF-β combined with IL-6 or IL-21 (Figs 3h and 4a). However,   
production of IL-21 and IL-10 was comparable in WT and Irf8–/–  
TH17  cells  (Fig.  4b–e).  These  results  suggest  that  an  autocrine   
loop involving either IL-21 or IL-10 is not involved in the functional 
control of TH17 differentiation by IRF8.
We  next  determined  whether  the  induction  of  TH17-associ-
ated genes may be affected by forced expression of IRF8 in T cells.   
Retroviral transduction of IRF8-IRES-GFP into WT naive CD4 +  T 
cells significantly decreased the percentage of IL-17-producing cells 
under TH17 polarizing conditions (Fig. 5a), and RORγt-positive cells   
were moderately reduced (Fig. 5a). Similarly, retroviral transduc-
tion of IRF8 into the EL4T lymphoma cell line stimulated with 
PMA/ionomycin resulted in significantly reduced transcripts for   
IL-17, but had no effect on the expression of interferon (IFN)-γ, IL-4, 
IL-10 or FOXP3 (Fig. 5b). Taken together, these results demonstrate 
a direct role for IRF8 in suppressing TH17-specific gene expression.
IRF8 interacts with RORγt and suppresses IL-17 transcription. 
The above findings prompted us to probe the molecular basis for 
IRF8  control  of  TH17-cell  differentiation.  As  many  studies  have 
demonstrated a critical role for RORγt in TH17-cell differentiation 
both in vitro and in vivo11, we asked if IRF8 might affect RORγt-
mediated IL-17 induction. EL4 cells were transiently transfected 
RORγt followed by stimulation with PMA/ionomycin. Overexpres-
sion of RORγt resulted in significantly increased expression of IL-17 
and IL-17F, whereas co-transfection with IRF8 greatly reduced the 
expression  of  these  genes,  suggesting  that  IRF8  inhibits  RORγt-
induced expression of IL-17 transcripts (Fig. 6a). Using a 6-kbp   
IL-17 promoter reporter plasmid, we confirmed that RORγt strongly 
induced IL-17 promoter reporter activity in 293T cells (Fig. 6b),   
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which was shown to be due to a direct effect of RORγt on the   
IL-17 promoter26,27. Co-transfection of IRF8 in these cells suppressed 
RORγt-mediated  IL-17  promoter  activity  in  a  dose-dependent   
manner (Fig. 6c). Similar results were observed in EL4 cells (Fig. 6d). 
CNS2 is a conserved non-coding sequence (CNS) element ~5 kbp 
upstream of the IL-17 locus that functions as a RORγt-depend-
ent enhancer element required for optimal IL-17 transcription27,28. 
Overexpression of IRF8 significantly suppressed CNS2-enhanced 
IL-17  promoter  activity  (Fig.  6e),  indicating  that  IRF8  inhibits   
IL-17 transcription.
To investigate whether IRF8 can directly bind the CNS2 region 
of  the  IL-17  promoter,  we  co-transfected  an  IL-17  promoter 
reporter  (containing  CNS2)  and  IRF8  plasmids  into  293T  cells   
and performed chromatin immunoprecipitation (ChIP) using an 
IRF8-specific antibody. The precipitated chromatin DNA was ana-
lysed by qPCR using primers covering the CNS2 region of the IL-17 
promoter. The results showed that IRF8 antibody specifically pulled 
down the CNS2 region sequences (Fig. 6f). To confirm the results, 
naive WT and Irf8–/– CD4 +  T cells were stimulated under TH17 
polarizing conditions for 60 h and ChIP assay was performed as 
above. The precipitated chromatin DNA was analysed by PCR using 
primers covering the CNS2 region of the IL-17 promoter. Similarly, 
IRF8 antibody specifically pulled down the CNS2 region sequences 
of TH17 cells from WT mice but not from Irf8–/– mice (Fig. 6g). 
These results demonstrate that IRF8 bound directly to this region of 
the IL-17 promoter. Further analyses of the CNS2 sequence revealed 
several IRF consensus binding sequence elements (Supplementary 
Fig. S6a). We showed that mutation of a typical IRF-binding site 
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in the CNS2 region of IL-17 promoter nullified the inhibition of 
RORγt-mediated  IL-17  promoter  activation  by  IRF8  (Supple-
mentary  Fig.  S6b).  These  results  provided  a  molecular  basis  for   
understanding the inhibitory effects of IRF8 on IL-17 transcrip-
tion. It is likely that RORγt cooperates with other known transcrip-
tion factors, such as FOXP3 or RUNX1, or unknown factors in the   
coordinate regulation of TH17 differentiation26,29,30. We then co-trans-
fected HA-tagged IRF8 and T7-RORγt plasmids into 293T cells for 
co-immunoprecipitation. Immunoprecipitation of RORγt resulted 
in co-precipitation of IRF8 (Fig. 7a), even in the presence of ethid-
ium bromide or DNase I, indicating that IRF8 and RORγt interact 
with each other without the involvement of DNA. Using confocal 
microscopy, we also determined that IRF8 and RORγt co-localized 
in the nucleus of NIH3T3 cells co-transfected with GFP-IRF8 and 
T7-RORγt constructs (Fig. 7b). Flow cytometric analyses of naive 
CD4 +  T cells stimulated under TH17 polarizing conditions clearly 
revealed a population of RORγt + CD4 +  cells with the majority of 
these cells also staining for IRF8 (Fig. 7c). Furthermore, anti-IRF8 
antibodies were found to co-immunoprecipitate RORγt from lysates 
of primary CD4 +  T cells from WT but not from Irf8–/– mice cul-
tured under TH17 polarizing conditions (Fig. 7d), indicating that 
endogenous IRF8 and RORγt interact with each other. As shown 
in Figure 7e, IRF8 is comprised of an N-terminal DNA-binding 
domain, a flanking internal region, and a C-terminal IRF associa-
tion domain31. To map the binding sites between IRF8 on RORγt, we 
co-transfected 293T cells with T7-tagged RORγt and Flag-tagged 
full-length IRF8 or one of a series of C-terminal truncation mutants 
(1–390, 1–356, 1–305, 1–253, 1–230, 1–190 and 1–154) followed by 
co-immunoprecipitation experiments. The results showed that IRF8 
amino-acid residues between 230 and 190 were important for the 
physical interaction with RORγt (Supplementary Fig. S7a, Fig. 7f).   
IRF8  mutant  (1–114),  which  is  not  bound  to  RORγt,  did  not   
suppress RORγt-mediated IL-17 promoter activation as WT and 
other binding mutants did (Fig. 7g and Supplementary Fig. S7b), 
demonstrating that the inhibitory activity of IRF8 on IL-17 trans-
cription is related to its interaction with RORγt. In addition, IRF4, 
another  IRF  family  member  that  is  required  for  the  generation   
of TH17 cells32, was also found in co-immunoprecipitation experi-
ments to interact with RORγt, whereas there was no interaction 
between  IRF1  and  RORγt  (Supplementary  Fig.  S8a).  Although   
transcript levels for IRF4 in cells deficient in IRF8 did not change 
under TH17 polarizing conditions (Supplementary Fig. S8b), we still 
cannot exclude possibility that IRF8 and IRF4 mutually influence 
their activities in TH17 cells. Thus, our results suggest that protein– 
protein interactions between IRF8 and RORγt have at least a partial 
role in IRF8-mediated inhibitory effects on IL-17 transcription.
IRF8 controls TH17-cell differentiation in vivo. To further assess 
the effects of IRF8 on TH17-cell differentiation in vivo, we performed 
adoptive transfer experiments using CD4 + CD62L + CD45RBhiCD25–  
cells  from  WT  and  Irf8–/–  mice  to  induce  colitis  in  RAG1  KO   
(Rag1–/–)  mice.  Irf8–/–  mice  did  not  develop  spontaneous  colitis   
during  an  observation  period  of  1.5  years  (Fig.  8a,b).  However, 
Rag1–/– mice reconstituted with Irf8–/– naive CD4 +  T cells began   
losing weight earlier and lost more weight than mice in the control 
group. Parallel histological studies of colon sections from Rag1–/– 
mice reconstituted with Irf8–/– T cells revealed more severe inflam-
matory cell infiltrates and significantly higher pathological scores 
than those observed in sections from mice reconstituted with T cells   
from WT mice (Fig. 8c–e). In addition, mice reconstituted with   
Irf8–/– cells had a significantly higher percentage of IL-17-producing 
cells than control mice (Fig. 8f). To determine whether Treg cells from 
Irf8–/– mice could suppress effector T cells, we examined the popula-
tion of Treg cells in Rag1–/– mice after the transfer of naive WT or Irf8–/–   
CD4 +  T cells. Rag1–/– recipients of naive CD4 +  T cells from mice 
of either genotype generated a small percentage of CD4 + FOXP3 +  
and CD4 + IFN-γ +  cells in the mesenteric lymph nodes (Fig. 8f).   
Furthermore, co-transfers of naive WT CD4 +  T cells with CD4 +  
CD25 +  cells purified from WT or Irf8–/– mice resulted in similar effects   
on  body  weight  (Supplementary  Fig.  S9).  These  results  indicate 
that the effects of IRF8 deficiency on T cell-mediated inflammation 
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were prepared, and the cells were stimulated with anti-CD3 and anti-CD28 
antibodies in the presence or absence of TGF-β plus IL-21 or IL-6 for 72 h. 
Intracellular staining for IL-17 and IFn-γ expression was performed and 
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representative of three independent experiments. Error bars, s.d. naive 
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(d). Data are from one experiment representative of three independent 
experiments. Error bars, s.d. naive CD4 +  T cells were stimulated with  
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could not be explained by influences on the function of CD4 +  Treg 
cells. Thus, IRF8 deficiency promotes intestinal inflammation in a   
T cell-mediated model of colitis, suggesting that IRF8 may have an 
inhibitory role in the control of TH17-mediated immune responses. 
To further understand the role of IRF8 in TH17-cell differentiation 
in vivo, we extended our observations to an infection model, as TH17 
cells have also been proposed to have a role in inflammation against 
both  intracellular  and  extracellular  bacteria33,34.  Staphylococcus 
aureus is a Gram-positive bacterium that can induce IL-17 pro-
duction from CD4 +  T cells mainly through Staphylococcus aureus 
enterotoxin A (SEA), and humans deficient in TH17 cells are highly 
susceptible to infection with this agent35,36. To better understand the 
regulatory effects of IRF8 on TH17-cell differentiation in a broader 
sense, we used superantigenic S. aureus to induce IL-17 produc-
tion in vivo. Spleen cells from Lck-Cre + Irf8fl/fl and Lck-Cre + Irf8wt/wt  
littermate controls immunized with SEA 4 days previously were 
re-stimulated in vitro with SEA for an additional 2 days and then 
examined  for  IL-17-producing  CD4 +   T  cells  by  flow  cytometry   
and for IL-17 secretion by ELISA (Supplementary Fig. S10). IRF8-
deficient mice generated significantly more IL-17-producing CD4 +  
T  cells  than  WT  mice,  further  confirming  that  IRF8  negatively   
regulates TH17-cell differentiation in vivo.
Discussion
TH17 cells represent a recently defined member of a still growing 
family of T helper cells. The mechanisms involved in the silencing 
programme for this T helper subset remain unclear. Here we demon-
strate that IRF8 serves as an intrinsic silencer for TH17-cell differen-
tiation. IRF8-deficiency in both conventional and T cell-specific 
conditional KO mice led to more robust TH17-cell differentiation 
without effects on either TH1 or TH2 cell lineages. Furthermore, 
transfer of IRF8–/– CD4 + CD45Rbhi cells into Rag1–/– mice induced 
more severe colitis than transfer of WT CD4 + CD45Rbhi cells. In 
addition, mice reconstituted with IRF8–/– cells had a significantly 
higher percentage of IL-17-producing cells than mice reconstituted 
with WT cells. In addition, we showed that IRF8 physically interacts 
with RORγt resulting in suppression of IL-17 transcription. These 
results suggest that IRF8 negatively regulates the development of 
TH17 immune response resulting in the control of inflammation.
Many  studies  have  demonstrated  that  IRF8  has  important   
functions in myeloid cells24. Macrophages from Irf8–/– mice did not 
produce IL-12 in response to IFN-γ and LPS. IRF8 regulates IL-12 
expression by binding to the IL-12 p40 promoter region, acting in 
synergy with IRF1 to activate IL-12 p40 gene expression37. In addi-
tion, IRF8 also induces the expression of other inflammatory pro-
teins expressed by myeloid cells, including iNOS, IL-18 and IL-1 
(refs 38–40). IRF8 protein levels are controlled in part by Cbl-medi-
ated  ubiquitylation  and  subsequent  proteasomal  degradation41. 
More recent studies have shown that transcriptional activation of 
IL-12p40 by IRF8 is enhanced following ubiquitylation by the E3 
ubiquitin  ligase,  TRIM21  (ref.  42).  Here,  we  showed  that  CD4 +   
T cells clearly expressed IRF8 protein on TCR engagement and that 
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TH17 polarization conditions induced stable IRF8 protein expres-
sion. In addition, mitogen-activated protein kinase inhibitors com-
pletely blocked IRF8 protein expression induced by TCR activation 
and STAT3 mutant mice showed impaired IRF8 mRNA expression, 
indicating that the TCR signalling cascade is involved in induction 
of IRF8 expression. The percentages of CD4 +  T cells in tissues of 
Irf8–/– and WT mice were comparable. Following stimulation under 
TH17  polarizing  conditions,  however,  the  percentages  of  IL-17-
producing CD4 +  T cells were greatly increased and the expression 
of TH17 signature genes was significantly enhanced for cells from   
Irf8–/– as compared with WT mice. These results suggest that IRF8   
is  an  important  transcription  factor  in  controlling  CD4 +   T  cell   
plasticity by targeting TH17-cell differentiation.
The  balance  between  pathogenic  TH17  cells  and  suppressive   
Treg  cells  in  the  immune  system  depends  on  the  presence  of   
inflammatory cytokines such as IL-6 and IL-21 (ref. 43). The anti-
inflammatory cytokine, TGF-β, combined with IL-6 or IL-21 can 
drive the conversion of a TH cell phenotype from TGF-β-induced 
FOXP3-expressing Treg cells to RORγt-expressing TH17 cells. TGF-β  
inhibits  the  expression  of  STAT4  and  GATA3,  thereby  prevent-
ing the differentiation of TH1 and TH2 cells, respectively, and con-
currently  facilitating  TH17-cell  development.  CD4 +   T  cells  from   
WT and Irf8–/– mice yielded similar populations of FOXP3 +  cells 
following  stimulation  under  TH17-  or  Treg-inducing  conditions.   
In addition, there were no significant differences between WT and 
Irf8–/– TH17 cells in the production of the autocrine cytokines, IL-21   
and  IL-10.  These  results  rule  out  the  possibility  that  enhanced   
generation of TH17 cells by CD4 +  T cells from Irf8–/– mice stimulated 
with TGF-β plus IL-6 was due to alterations in TGF-β-derived Treg 
suppression or to an autocrine loop involving IL-21 or IL-10.
IRF8  acts  as  a  transcriptional  repressor  or  a  transcriptional   
activator depending on the target DNA sequence and interactions 
with different partner proteins, including PU.1, E47 and other IRFs25. 
We demonstrated that IRF8 interacts directly with RORγt, result-
ing in suppression of IL-17 transcription. The association of IRF8   
with RORγt was not competed by FOXP3, another RORγt-binding 
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protein44, indicating that IRF8 antagonizes the effect of RORγt with-
out the involvement of FOXP3. In addition, co-immunoprecipita-
tion studies showed that IRF4, another IRF family member required 
for TH17-cell differentiation32, also interacts with RORγt. It is likely 
that  RORγt  cooperates  with  other  transcription  factors,  such  as 
FOXP3 or RUNX1, or unknown factors in the regulation of TH17 
differentiation26,29–30. It remains to be determined how these factors 
might collaborate with RORγt, the master transcription factor for 
TH17 cells to regulate differentiation of this TH subset.
TH17 cells are critical pathogenic effector T cells in inflammatory 
disorders such as inflammatory bowel disease45–47. In the present 
study, we demonstrated that IRF8 targets RORγt, resulting in the 
silencing of TH17-cell differentiation. In addition, transfer of IRF8–/–  
CD4 + CD45Rbhi cells into Rag1–/– mice induced more severe colitis 
than transfer of WT cells. These results suggest that IRF8 functions 
as an important transcription factor in the control of inflammation 
by modulating RORγt activity. A recent genome-wide association 
study  identifying  IRF8  as  a  susceptibility  locus  in  patients  with 
multiple sclerosis48 is supportive of this model for IRF8 function   
in inflammatory diseases. As a result, our data may provide a mole-
cular basis for identifying specific single-nucleotide polymorphisms 
associated with susceptibility to clinical immune pathologies.
Taken  together,  our  results  demonstrate  that  IRF8  is  stably 
expressed during TH17-cell differentiation and has a critical role   
in directing the silencing programme for TH17-cell development. 
On the basis of these studies, we propose a novel molecular mecha-
nism for the inhibitory effects of IRF8 on TH17 differentiation and 
cytokine expression that involves the modulation of RORγt activity 
(Supplementary Fig. S11). Our observations support a pathogenic 
role for TH17 cells in exacerbating inflammation and indicate that 
IRF8 may be a therapeutic target for controlling TH17-mediated 
autoimmune and inflammatory diseases.
Methods
Mice. C57BL/6 (B6) and B6-Irf8–/– mice were maintained in the barrier facility at 
the Mount Sinai School of Medicine. GFP-FOXP3 mice were crossbred with Irf8–
/– mice to obtain Irf8–/–GFP-FOXP3 mice. IRF8 conditional knockout mice (Irf8fl/fl) 
were generated at Ozgene under a contract with NIAID by flanking exon 2 and  
an inserted PGK-neo cassette with loxP sites. Following homologous recombina-
tion of the targeting vector in C57BL/6 ES cells and establishment of germ line 
transmission, the PKG-neo cassette, which was flanked by flippase recognition 
target (FRT) sites, was excised by crossing with a FLP transgenic mouse. Selective 
breeding was used to eliminate the FLP gene. Conditional deletion of IRF8 in  
T cells was performed by crossing with Lck-Cre mice to generate Lck-Cre + Irf8fl/fl 
mice. The animal study protocols were approved by the Institutional Animal Care 
and Use Committees of Mount Sinai, NICHD and NIAID (protocol LIP-4).
Antibodies. The following antibodies were purchased from BD Biosciences, as 
conjugated to FITC, PE, PE-Cy5, perCP-Cy5.5 or APC: CD4 (L3T4), CD8 (53-6.7), 
CD3e (145-2C11), CD25 (PC61.5), CD44 (IM7), CD62L (MEL-14), CD45RB 
(C363-16A), IL-17 (TC11-18H10), IFN-γ (XMG1.2), TCRβ chain (H57-597) and 
isotype controls. Antibodies for IL-2 (JES6-1A12), IL-4 (11B11), IL-10 (JES5-16E3) 
and Foxp3 (FJK-16S) were purchased from eBiosciences.
CD4 +  T cell preparation and differentiation in vitro. Naive CD4 +  T cells 
(CD62L + CD44lo) were prepared by fluorescence-activated cell sorting from spleens 
and lymph nodes of Irf8–/– and WT littermates. The sorted cells were primed for 
96 h with anti-CD3 (1 µg ml − 1; 145-2C11; BD Biosciences) and soluble anti-CD28 
(2 µg ml − 1; 37.51; BD Biosciences). The cells were rested for 48 h, and were then 
re-stimulated for 5 h with PMA plus ionomycin in the presence of brefeldin A and 
intracellular cytokines were measured by flow cytometry. Cells stimulated under 
neutral conditions were defined as TH0 cells. Cells were stimulated to differentiate 
into TH1 cells by supplementation with IL-12 plus anti-IL-4 (10 µg ml − 1; 11B11; 
BD Bioscences) or into TH2 cells by supplementation with IL-4 and anti-IFN-γ 
(10 µg ml − 1; XMG1.2, BD Biosciences). For TH17-cell differentiation, cells were 
stimulated with transforming growth factor-β1 (5 ng ml − 1), IL-6 (20 ng ml − 1) and 
IL-23 (10 ng ml − 1; all from R&D Systems) in the presence of anti-IL-4 antibody 
(10 µg ml − 1; 11B11, BD Bioscences) and anti-IFN-γ antibody (10 µg ml − 1; XMG1.2, 
BD Biosciences).
Intracellular staining and flow cytometry. Cells were stimulated with PMA and 
ionomycin for 5 h in the presence of brefeldin A before intracellular staining. Cells 
were fixed with IC Fixation Buffer (BD Biosciences), incubated with permeabiliza-
tion buffer, and stained with PE-anti-mouse IL-17, APC-anti-IFN-γ and PE-Cy 
5.5 anti-mouse CD4 antibodies. Flow cytometry was performed on a FACSCalibur 
(BD Biosciences) and LSR Fortessa (BD Biosciences).
RNA isolation and quantitative real-time RT–PCR. Total RNA was extracted 
using an RNeasy plus kit (QIAGEN) and cDNA was generated with an oligo (dT) 
primer and the Superscript II system (Invitrogen) followed by analysis using 
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Figure 7 | IRF8 interacts physically with RORγ. (a) 293T cells were 
transfected with HA-tagged IRF8 and T7-tagged RoRγt overexpression 
plasmids for 40 h and cell lysates were prepared in the presence or 
absence of Dnase I or ethidium bromide. 500 µg of cell lysates were 
immunoprecipitated with an anti-T7 antibody and immunoblotted 
with specific antibodies as indicated. Data are representative of three 
independent experiments. (b) nIH3T3 cells were transiently transfected 
with GFP-IRF8 and T7-RoRγt for 40 h, and cells were fixed and stained  
red for RoRγt followed by confocal microscopic analysis. scale bar, 50 µm. 
(c) naive CD4 +  T cells from WT mice were cultured under TH17-polarizing 
conditions for 72 h and the expression of RoRγt and IRF8 was analysed  
by flow cytometry. The cells were gated on CD4 +  T cells. Data  
are representative of three independent experiments. (d) naive CD4 +   
T cells from wild-type or Irf8–/– mice were cultured under TH17-polarizing 
conditions for 60 h and the cell lysates were then immunoprecipitated  
with an anti-IRF8 antibody and western blotted (WB) with anti-RoRγt  
and anti-IRF8 antibodies. Data represent three independent experiments. 
(e) Diagrams of IRF8 protein domains. (f) 293T cells were co-transfected 
with plasmids containing Flag-tagged full-length IRF8, IRF8 fragments 
(1–230, 1–190, 1–154) and T7-tagged RoRγt plasmid for 40 h, and  
co-immunoprecipitation using anti-Flag antibody from the cell extracts 
was performed and immunoblotted with anti-T7 antibody. Data are 
representative of three independent experiments. (g) 293T cells were 
co-transfected with an IL-17 promoter reporter construct containing the 
6-kbp promoter, a RoRγt plasmid and either a full-length IRF8 or the 
IRF8 truncation mutant (1–114) construct for 30 h. Luciferase assays were 
performed as described in b. Data indicate mean ± s.d. of triplicate cultures 
and are representative of three independent experiments. *P < 0.05 versus 
cells transfected with IRF8 mutant (student’s t-test).ARTICLE
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iCycler PCR with SYBR Green PCR master Mix (Applied Biosystems). Results were 
normalized based on the expression of ubiquitin. The following primer sets were 
used: IL-17A, IL-17F, IL-21, IL-23R, RORγt, IFN-γ, IRF8, IRF1 IRF4 T-bet FOXP3, 
CCR6, IL-10, IL-4, IL-2 and ubiquitin (Supplementary Table S1).
Transfection and luciferase reporter assay. 293T cells were transiently trans-
fected with an IL-17 promoter luciferase reporter plasmid together with RORγt 
in the presence of IRF8 plasmid at different concentrations. For each transfec-
tion, 2.0 µg of plasmid was mixed with 100 µl of Opti-MEM I medium (without 
serum and antibiotics) and 4.0 µl of Lipofectamine 2000 reagent. The mixture was 
incubated at room temperature for 20 min and added to 12-well plates containing 
cells and complete medium. The cells were incubated for 30 h and collected using 
reporter lysis buffer (Promega) for determination of luciferase activity. Cells were 
co-transfected with a β-galactosidase reporter plasmid to normalize experiments 
for transfection efficiency.
Generation of the mutant IL-17 promoters. A predicted IRF-binding site 
adjacent to the downstream RORγt-binding site in the CNS2 region of the mouse 
IL-17A promoter was mutated using QuickChange XL Site-Directed Mutagenesis 
Kit (Stratagene) according to manufacture’s instruction. Two mutations were intro-
duced on the IL-17 promoter regions  − 5204 to  − 5202 (TGG to CCC) and  − 5201 
to  − 5199 (AAA to CCC) from the transcriptional initiation site ( + 1) using the fol-
lowing primer sets: 5′-GGTTGGAAAAAAAAACCCAAAGTTTTCTGACCCA-3′ 
and 5′-TGGGTCAGAAAACTTGGGTTTTTTTTTCCAACC-3′ for TGG to CCC; 
5′-TGGAAAAAAAAATGGCCCGTTTTCT-GACCCACT-3′ and 5′-AGTGGGTC 
AGAAAACGGGCCATTTTTTTTTCCA-3′ for AAA to CCC. Mutations were 
verified by sequencing.
Retroviral transduction of IRF8 in CD4 +  T cells. To prepare pseudotyped virus 
human 293 EbnaT cells were seeded at a density of 4×106 cells in a 10-cm dish. The 
next day, cells were transfected using calcium phosphate with a mixture of 2.5 µg 
of plasmid pMD.G encoding vesicular stomatitis virus G protein, 7.5 µg of plasmid 
encoding gag-pol, and 10 µg of a retroviral expression constructs encoding GFP or 
IRF8. At 48 h after transfection, the viral supernatant was collected, centrifuged at 
800g, and used to infect cells. CD4 +  T-cell transduction was performed as previ-
ously described11, sorted naive CD4 +  T cells were plated as above and cultured for 
24 h in the presence of anti-CD3 (1 µg ml − 1; 145-2C11, BD Biosciences) and soluble 
anti-CD28 (2 µg ml − 1; 37.51; BD Biosciences). Activated cells were then transduced 
with fresh retrovirus supernatant by centrifugation for 1.5 h at 2000g in the pres-
ence of polybrene (6 µg ml − 1; Sigma). After 24 h, the cells were re-transduced using 
the same procedure and cultured for an additional 24 h and were then stimulated 
with TGF-β and IL-6. The cells were collected on day 5 or 6 for intracellular 
cytokine staining.
T-cell proliferation assay. Naive CD4 +  T cells were purified from spleens and 
lymph nodes of Lck-Cre + Irf8fl/fl and Lck-Cre + Irf8wt/wt littermate controls. Cells 
(1×105 per well) were cultured in the absence or presence of anti-CD3 (1 µg ml − 1) 
and anti-CD28 (2 µg ml − 1) antibodies for 3 days in 96-well microplates. [3H]-Thy-
midine was added during the last 8 h of a 72-h culture. The cells were then collected 
and counted with a beta-counter.
Co-immunoprecipitation and immunoblotting analysis. Cells were washed with 
cold phosphate-buffered saline and lysed for 15 min on ice in 0.5 ml of lysis buffer 
(50 mM Tris-HCl, pH 8.0, 280 mM NaCl, 0.5% Nonidet P-40, 0.2 mM EDTA, 2 mM 
EGTA, 10% glycerol and 1 mM dithiothreitol) containing protease inhibitors. 
Cell lysates were clarified by centrifugation (4 °C, 15 min, 20,000 r.p.m.), aliquots 
(500 µg) were incubated with 2 µg of normal rabbit IgG for 4 h and 20 µl of protein 
G-Sepharose was added to the mixture for 2 h. After centrifugation, the superna-
tant was collected and incubated with 2 µg of anti-Flag antibody overnight at 4 °C 
with gentle rocking, after which immune complexes were collected as described 
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Figure 8 | Lack of IRF8 enhances the TH17 immune response in experimental colitis. WT and Irf8–/– mice were maintained under specific pathogen free (sPF). 
conditions for up to 18 months. mice were killed and intestines were removed for histological analysis. Histology of colon tissues (a) and disease score  
(b) from age-matched young (15 weeks) and old (17–18 months) WT and Irf8–/– mice (three to four mice in each group). scale bars, 200 µm. CD4 + CD45RBhi 
T cells were purified from spleens and lymph nodes of wild-type or Irf8–/– mice and 5×105 cells were injected (i.p.) into recipient Rag–/– mice. Body 
weight change was monitored every week and mice were killed 7 weeks later. (c) Changes in body weight of Rag1–/– mice (n = 5–6 mice per group) after 
intraperitoneal transfer of WT or Irf8–/– CD4 + CD45RBhi T cells were recorded. Data are presented as the mean ± s.d. of the percentage of initial body weight 
and are representative of two similar experiments. *P < 0.05 versus recipients of WT cells (AnoVA test and student’s t-test). Disease scores (d) and 
sections of colons with colitis (e) from Rag1–/– mice (n = 5–6 mice in each group) on day 35 after naive T cell transfer as described in c. *P < 0.05 versus  
recipients of WT cells (mann–Whitney test). scale bars, 200 µm. (f) The percentage of IL-17, IFn-γ and FoXP3-producing cells from mesenteric lymph 
nodes of Rag1–/– mice in c (white column, transfer with WT cells; black column, transfer with Irf8–/– cells). **P < 0.01 versus wild-type cell transferred mice 
(student’s t-test). Data are presented as the mean ± s.d. from four mice in each group. Two independent experiments were performed with similar results.ARTICLE     
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above with 20 µl of protein G-Sepharose. After washing five times with lysis buffer, 
immunoblotting was performed. Anti-Flag (Sigma), anti-IRF8 (Santa Cruz), 
anti-β-actin (Sigma) and anti-T7 (MBL) antibodies were used according to the 
manufactures’ instructions. Secondary antibodies were from Santa Cruz.
T-cell-transfer colitis studies and histopathology. T-cell-transfer colitis was 
performed as previously described49,50. Briefly, purified CD4 + CD45RBhi T cells 
from WT and Irf8–/– mice were injected intraperitoneally into Rag1–/– recipients 
(5×105 cells per mouse in 200 µl sterile PBS per injection). Mice were weighed 
every week throughout the course of experiments. After 5 weeks, mice were killed 
and colon tissues were excised. Tissues were fixed in 10% buffered formalin and 
paraffin embedded. The sections (5 µm) of tissue samples stained with hematoxylin 
and eosin. All the slides were read and scored by an experienced pathologist (L.Q.) 
without previous knowledge of the type of treatment. The degree of inflammation 
in the epithelium, submucosa and muscularis propria was scored separately as 
described by Totsuka et al.49
In vivo stimulation of TH17 cells by Staphylococcus aureus. Lck-Cre + Irf8fl/fl mice 
and Lck-Cre + Irf8wt/wtl littermate controls were immunized (i.p.) with SEA (10 µg per 
mouse) for 4 days. Mice were killed and spleen cells were prepared. The cells were 
re-stimulated in vitro with SEA (10 ng ml − 1) for additional 2 days and cells were 
collected for the analysis of IL-17-producing CD4 +  T cells by flow cytometry gat-
ing on CD4 +  T cells. The supernatants were collected for the measurement of IL-17 
production by ELISA.
Chromatin immunoprecipitation assay. The ChIP procedure was performed 
using an assay kit following the manufacturer’s instruction (Upstate Biotechnol-
ogy). Briefly, 293T cells were co-transfected with an IL-17 promoter containing 
CNS2 domain and an IRF8 plasmid for 36 h and 1×107 transfected cells were then 
crosslinked by 1% formaldehyde for 10 min at 37 °C. Nuclei were prepared and 
subjected to sonication to obtain DNA fragments. Chromatin fractions were pre-
cleared with protein A-agarose beads followed by immunoprecipitation overnight 
at 4 °C with 3 µg of anti-IRF8 or control antibody. Crosslinking was reversed at 
65 °C for 4 h, followed by proteinase K digestion. DNA was purified and subjected 
to qPCR. The input DNA was diluted 200 times before PCR amplification. The 
input and immunoprecipitated DNA were amplified by qPCR using primers  
(5′-CAGCCCTGGTCCTTAAACTG-3′ and 5′-TCACTTTCGTTGTGCCTTTG-3′) 
encompassing the CNS2 region of the mouse IL-17 promoter.
Cytokine ELISA. Supernatants from cell cultures were collected after activation  
under various conditions and secreted cytokines in the supernatants were meas-
ured by ELISA kits with purified coating and biotinylated detection antibodies: 
anti-IL-17, anti-22 and anti-IL-21 (R&D systems), anti-IFN-γ, anti-IL-4 and  
anti-IL-10 (BD Bioscience).
Statistical analysis. Statistical analysis was performed using Student’s t-test for 
most of the experiments. For colitis experiments, Man–Whitney test and analysis 
of variance test were used for comparison of disease score and weight loss.  
P values  < 0.05 were considered statistically significant. 
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